172@29@17@243!~!172@29@0@53!~!|news|tags|glenmark-pharmaceuticals.html!~!news|moneycontrol|com!~!|controller|tag.php!~!is_mobile=false
glenmark pharmaceuticals
Jump to
188 Results Found
  • Sell Glenmark Pharmaceuticals; target of Rs 365: Prabhudas Lilladher Aug 20, 2020 12:35 PM IST

    Sell Glenmark Pharmaceuticals; target of Rs 365: Prabhudas Lilladher

    Prabhudas Lilladher is bearish on Glenmark Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 365 in its research report dated August 18, 2020.

  • Buy Glenmark Pharmaceuticals; target of Rs 560: ICICI Direct Aug 19, 2020 11:02 AM IST

    Buy Glenmark Pharmaceuticals; target of Rs 560: ICICI Direct

    ICICI Direct is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 560 in its research report dated August 17, 2020.

  • Glenmark Pharmaceuticals Q1 net jumps over two-fold to Rs 254 crore Aug 14, 2020 10:08 PM IST

    Glenmark Pharmaceuticals Q1 net jumps over two-fold to Rs 254 crore

    The company had reported a net profit of Rs 109.28 crore for the April-June period of 2019-20.

  • Glenmark cuts price of COVID-19 drug by 27% to Rs 75 per tablet Jul 13, 2020 07:34 PM IST

    Glenmark cuts price of COVID-19 drug by 27% to Rs 75 per tablet

    The company has also completed the phase 3 clinical trial with Favipiravir (FabiFlu) in mild to moderate COVID-19 patients in India.

  • Sell Glenmark Pharmaceuticals; target of Rs 365: Prabhudas Lilladher Jul 02, 2020 01:52 PM IST

    Sell Glenmark Pharmaceuticals; target of Rs 365: Prabhudas Lilladher

    Prabhudas Lilladher is bearish on Glenmark Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 365 in its research report dated June 29, 2020.

  • Glenmark Pharma falls 5% on CLSA downgrade after Q4 earnings Jun 30, 2020 03:30 PM IST

    Glenmark Pharma falls 5% on CLSA downgrade after Q4 earnings

    Glenmark reported 36 percent year-on-year increase in Q4FY20 profit at Rs 220 crore and 8 percent growth in revenue at Rs 2,764 crore during the quarter compared to year-ago.

  • Glenmark Pharma Q4 net profit jumps 36% to Rs 220 crore Jun 26, 2020 10:41 PM IST

    Glenmark Pharma Q4 net profit jumps 36% to Rs 220 crore

    The company's consolidated revenue for the quarter rose 7.96 per cent to Rs 2,767.48 crore as against Rs 2,563.47 crore a year ago, Glenmark Pharmaceuticals said in a regulatory filing.

  • Glenmark Pharma corrects 7% on profit booking Jun 24, 2020 12:59 PM IST

    Glenmark Pharma corrects 7% on profit booking

    Prabhudas Lilladher says 27 percent rally in the stock on June 22 was an "irrational exuberance" and would likely fizzle out.

  • Sell Glenmark Pharmaceuticals; target of Rs 257: Prabhudas Lilladher Jun 23, 2020 07:50 PM IST

    Sell Glenmark Pharmaceuticals; target of Rs 257: Prabhudas Lilladher

    Prabhudas Lilladher is bearish on Glenmark Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 257 in its research report dated June 23, 2020.

  • Remdesiver, Favipiravir antiviral drugs 'no game changers' in COVID fight, say medical experts Jun 22, 2020 08:27 PM IST

    Remdesiver, Favipiravir antiviral drugs 'no game changers' in COVID fight, say medical experts

    Dr Avi Kumar, Consultant, Pulmonologist, Fortis Escort Heart Institute, said drugs such as Favipiravir and Remdisiver "cannot be called game changers" as they are used as a supportive treatment.

  • Glenmark Pharmaceuticals gets India approval for favipiravir as COVID-19 treatment Jun 19, 2020 08:50 PM IST

    Glenmark Pharmaceuticals gets India approval for favipiravir as COVID-19 treatment

    The Mumbai-based company said the approval was part of India's accelerated approval process and the drug was meant for "restricted emergency use," meaning patients must sign their consent before being treated by the drug.

  • Glenmark Pharmaceuticals gets USFDA nod for Fingolimod capsules Jun 19, 2020 09:57 AM IST

    Glenmark Pharmaceuticals gets USFDA nod for Fingolimod capsules

    "Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation," the drug major said in a filing to BSE.

  • Buy Glenmark Pharmaceuticals; target of Rs 410: Globe Capital Market Jun 02, 2020 11:32 AM IST

    Buy Glenmark Pharmaceuticals; target of Rs 410: Globe Capital Market

    Globe Capital Market is bullish on Glenmark Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 410 in its research report dated Jun 01, 2020.

  • Glenmark Pharmaceuticals to study potential COVID-19 drug combination May 26, 2020 11:05 AM IST

    Glenmark Pharmaceuticals to study potential COVID-19 drug combination

    The study will look to enroll 158 hospitalized patients of moderate COVID-19 in India, the company added.

  • Glenmark inks licensing pact with Hikma for commercialisation of nasal spray Ryaltris in US Feb 27, 2020 02:50 PM IST

    Glenmark inks licensing pact with Hikma for commercialisation of nasal spray Ryaltris in US

    The licensing pact for Ryaltris has been signed between the company's Swiss subsidiary, Glenmark Specialty SA and Hikma Pharmaceuticals PLC (Hikma).

  • Glenmark Q3 net profit rises 64% to Rs 190.83 cr; to raise $400 mn Feb 14, 2020 09:16 PM IST

    Glenmark Q3 net profit rises 64% to Rs 190.83 cr; to raise $400 mn

    The company had posted a net profit of Rs 116.34 crore in the corresponding period of the previous financial year, Glenmark Pharmaceuticals said in a filing to the BSE.

  • Glenmark board to consider fund raising options on February 14 Feb 11, 2020 07:26 PM IST

    Glenmark board to consider fund raising options on February 14

    The Mumbai-based firm plans to raise funds either through issuance of bonds or debentures, non-convertible debt instruments or any other securities or any combination thereof, of any of the above, it added.

  • Mankind Pharma inks licensing pact with Glenmark to co-market diabetes drug Dec 23, 2019 01:59 PM IST

    Mankind Pharma inks licensing pact with Glenmark to co-market diabetes drug

    "This is particularly important in reducing overall disease burden. Moreover, this strategic decision will not only strengthen our diabetes portfolio but also help consolidate our position as the fastest-growing player in the anti-diabetes segment," Mankind Pharma Director of Marketing Sanjay Koul said in a statement.

  • Glenmark gets approval from Australian regulator to commercialise Ryaltris Dec 20, 2019 11:08 AM IST

    Glenmark gets approval from Australian regulator to commercialise Ryaltris

    Ryaltris is a new fixed dose combination nasal spray of an antihistamine and a steroid indicated for treatment of symptoms associated with allergic rhinitis and rhinoconjunctivitis in patients over 12 years of age in Australia.

  • Glenmark's Baddi manufacturing unit receives GMP certificate from European regulator Dec 16, 2019 10:45 AM IST

    Glenmark's Baddi manufacturing unit receives GMP certificate from European regulator

    "The European regulator has just issued a certificate of compliance for the facility stating that it complies with the principles and guidelines of Good Manufacturing Practice (GMP) laid down in the directive 2003/94/EC which stipulates the requirements to fulfil GMP recommendations of WHO," Glenmark Pharmaceuticals said in a regulatory filing.

  • Glenmark Pharma gets USFDA nod for diabetes management drug Nov 26, 2019 11:10 AM IST

    Glenmark Pharma gets USFDA nod for diabetes management drug

    Glenmark's current portfolio consists of 164 products authorised for distribution in the US marketplace and 44 abbreviated new drug applications pending approval with the USFDA.

  • Glenmark Pharmaceuticals Q2 net profit at Rs 255.54 cr Nov 14, 2019 08:56 PM IST

    Glenmark Pharmaceuticals Q2 net profit at Rs 255.54 cr

    Net sales of the company stood at Rs 2,763.73 crore, up 8.81 percent, during the period under review as against Rs 2,539.85 crore of the corresponding quarter previous fiscal.

  • Market Headstart: Nifty likely to open higher; HCL Tech, Biocon top buys Oct 07, 2019 08:38 AM IST

    Market Headstart: Nifty likely to open higher; HCL Tech, Biocon top buys

    Trends on SGX Nifty indicate a positive opening for the broader index in India, with a 17 points gain or 0.16 percent. The Nifty futures were trading around 11,223-level on the Singaporean Exchange.

  • Reorganisation of Glenmark into 3 entities to be concluded this fiscal: Glenn Saldanha Sep 03, 2019 09:06 PM IST

    Reorganisation of Glenmark into 3 entities to be concluded this fiscal: Glenn Saldanha

    In his message to the company's shareholders, Saldanha said the three entities will focus on different verticals -- generics, branded and specialty products; active pharmaceutical ingredients (API); and breakthrough innovative drugs.

  • Glenmark recalls products from US market Aug 25, 2019 12:28 PM IST

    Glenmark recalls products from US market

    The recall is a nationwide within the United States, the USFDA said.

Sections